- Current knowledge on the genetics of incident venous thrombosis
- Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups
- Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, Prothrombin 20210A and Methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls
- Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature
- Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic Analysis of Idiopathic Thrombophilia
ARTÍCULOS COMENTADOS
Los artículos más interesantes publicados sobre Enfermedad Tromboembólica
comentados por los profesores del curso
ÍNDICE DE ARTÍCULOS
- Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis
- Compression stockings to prevent post-thrombotic syndrome: a randomized placebo-controlled trial
- Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis
- Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
- Clinical and safety outcomes associated with treatment of acute venous thromboembolism. A systematic review and meta-analysis
- Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials.
- Fibrinolysis for patients with intermediate-risk pulmonary embolism
- Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis
- Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.
- Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis
- Clinical characteristics and long-term follow-up of patients with renal vein thrombosis
- Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis of observational studies
- Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry
- Revisión exhaustiva de 3 artículos sobre el manejo de las trombosis venosas en sitios inusuales
- Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature
- Peripherally Inserted Central Catheter-associated Deep Vein Thrombosis: A Narrative Review
- Noninvasive Imaging of Early Venous Thrombosis by 19F Magnetic Resonance Imaging With Targeted Perfluorocarbon Nanoemulsions
- D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis
- Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry
- Air travel and venous thromboembolism: minimizing the risk
- HDL cholesterol efflux capacity and incident cardiovascular events
- Compensatory enlargement of human atherosclerotic coronary arteries
- Vorapaxar in the Secondary Prevention of Atherothrombotic Events.
- Impact of statins on serial coronary calcification during atheroma progression and regression
- Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
- Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
- A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
- Duplex ultrasonography, magnetic resonance angiography, and computed tomography angiography for diagnosis and assessment of symptomatic, lower limb peripheral arterial disease: systematic review
- Prevalencia y características clínicas de la enfermedad arterial periférica en la población general del estudio Hermex
- Treatment of thromboangiitis obliterans (Buerger’s disease) with bosentan
- Factores relacionados con el riesgo de trombosis en pacientes con lupus y positividad para anticuerpos antifosfolipidicos
- Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study
- Clinical efficacy and safety of cilostazol: a critical review of the literature
- Detection of significant coronary artery disease by noninvasive anatomical and functional imaging
- Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes
- Prehospital ticagrelor in ST-segment elevation myocardial infarction
- Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction
- Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial
- Segment Elevation Acute Coronary Syndrome
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
- 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
- A randomized trial of intraarterial treatment for acute ischemic stroke
- Guidelines for the treatment of acuteischaemic stroke.
- Embolic strokes of undetermined source: the case for a new clinical construct
- Actualización del Plan de Atención Sanitaria al Ictus II.10
- Stroke and transient ischemic attack incidence rate in Spain: the IBERICTUS study
- 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
- Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study
- A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. The Euro Heart Survey on Atrial Fibrillation
- Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation
- Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with AF: nationwide cohort study
- Dose comparisons of clopidogrel and aspirin in acute coronary syndromes
- Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
- Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial
- Randomized comparative trial of triflusal and aspirin following acute myocardial infarction
- Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
- Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
- Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium
- Oral anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians. Evidence-based clinical practice guidelines
- Treatment and prevention of heparin-induced thrombocytopenia. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
- Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians. Evidence-based clinical practice guidelines.
- Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians. Evidence-based clinical practice guidelines.
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial
- Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
- Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation
- Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial
- Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials
- The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
- Dabigatran versus warfarin in patients with atrial fibrillation
- Comparison of Dabigatrán and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
- Uninterrupted Dabigatrán versus Warfarin for Ablation in Atrial Fibrillation
- Dual Antithrombotic Therapy with Dabigatrán after PCI in Atrial Fibrillation
- Idarucizumab for Dabigatrán Reversal – Full Cohort Analysis
- Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
- Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
- Efficacy and safety of edoxaban in comparison with dabigatran, Rivaroxaban and apixaban for stroke prevention in atrial fibrillation An indirect comparison analysis
- Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents
- European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
- Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
- Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials
- Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study
- Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
- Idarucizumab for Dabigatran Reversal
- Antidotes for novel oral anticoagulants: current status and future potential
- Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice
- Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Trastorno tromboembofílico
Current knowledge on the genetics of incident venous thrombosis
[vc_tta_section i_icon_fontawesome="fa fa-folder-open-o" title="Abstract" tab_id="1465910664342-b1e8ae30-39a0"... Leer más →
20 julio, 2016
Non-O blood type is the commonest genetic risk factor for VTE: results from a meta-analysis of the literature
[vc_row top_padding="30"... Leer más →
20 julio, 2016
Tratamiento de la trombosis venosa
Extended treatment of venous thromboembolism: a systematic review and network meta-analysis
[vc_tta_section i_icon_fontawesome="fa fa-folder-open-o" title="Abstract"... Leer más →
3 junio, 2019
Pharmacomechanical Catheter-Directed Thrombolysis for Deep Vein Thrombosis
Antecedentes El síndrome postrombótico... Leer más →
3 junio, 2019
“Oral anticoagulant therapy. Antithrombotic therapy and prevention of thrombosis.”
Background: The... Leer más →
27 mayo, 2019
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. Lee AY1, Levine MN, Baker RI, Bowden... Leer más →
27 mayo, 2019
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer A Randomized Clinical Trial Agnes Y. Y. Lee, MD,... Leer más →
27 mayo, 2019
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results... Leer más →
27 mayo, 2019
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer.
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. Carrier M1, Abou-Nassar K1, Mallick R1, Tagalakis V1, Shivakumar S1, Schattner... Leer más →
27 mayo, 2019
Compression stockings to prevent post-thrombotic syndrome: a randomized placebo-controlled trial
[vc_column... Leer más →
14 junio, 2016
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials
[vc_tta_section i_icon_fontawesome="fa... Leer más →
14 junio, 2016
Enfermedad tromboembólica pulmonar
Assessment of coexisting deep vein thrombosis for risk stratification of acute pulmonary embolism
Assessment of coexisting deep vein thrombosis for risk stratification of acute pulmonary embolism. Quezada CA1, Bikdeli B2, Barrios D1, Morillo... Leer más →
27 mayo, 2019
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d’Embolie Pulmonaire par Interruption Cave Study Group
A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention... Leer más →
27 mayo, 2019
Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry
Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. Jiménez D1, de Miguel-Díez J2,... Leer más →
27 mayo, 2019
Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism
Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism Liselotte M. van der Pol, M.D., Cecile Tromeur, M.D., Ingrid M. Bistervels,... Leer más →
27 mayo, 2019
Fibrinolysis for patients with intermediate-risk pulmonary embolism
[vc_row... Leer más →
15 junio, 2016
Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.
[vc_row top_padding="30"... Leer más →
15 junio, 2016
Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis
[vc_row... Leer más →
15 junio, 2016
Otros fenómenos trombóticos venosos
Clinical characteristics and long-term follow-up of patients with renal vein thrombosis
[vc_row top_padding="30"... Leer más →
7 julio, 2016
Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis of observational studies
[vc_row top_padding="30"... Leer más →
7 julio, 2016
Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry
[vc_row top_padding="30"... Leer más →
7 julio, 2016
Safety of thrombolysis in cerebral venous thrombosis. A systematic review of the literature
[vc_row top_padding="30"... Leer más →
7 julio, 2016
Enfermedad tromboembólica venosa periférica
Peripherally Inserted Central Catheter-associated Deep Vein Thrombosis: A Narrative Review
[vc_tta_section i_icon_fontawesome="fa fa-folder-open-o" title="Abstract"... Leer más →
27 julio, 2016
Noninvasive Imaging of Early Venous Thrombosis by 19F Magnetic Resonance Imaging With Targeted Perfluorocarbon Nanoemulsions
[vc_tta_accordion... Leer más →
27 julio, 2016
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis
[vc_column... Leer más →
27 julio, 2016
Air travel and venous thromboembolism: minimizing the risk
[vc_tta_section i_icon_fontawesome="fa fa-folder-open-o" title="Abstract"... Leer más →
27 julio, 2016
Fisiopatologia de la trombosis arterial
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Ridker PM, Libby P, Thuren T, MacFadyen JG, Everett BM, Glynn RJ, et al. Relationship of C-reactive protein reduction to... Leer más →
3 agosto, 2019
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management... Leer más →
27 mayo, 2019
“2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries”1
“2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS):... Leer más →
27 mayo, 2019
HDL cholesterol efflux capacity and incident cardiovascular events
HDL cholesterol efflux capacity and incident cardiovascular events Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin... Leer más →
1 septiembre, 2016
Compensatory enlargement of human atherosclerotic coronary arteries
Compensatory enlargement of human atherosclerotic coronary arteries Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. N Engl... Leer más →
1 septiembre, 2016
Vorapaxar in the Secondary Prevention of Atherothrombotic Events.
Vorapaxar in the Secondary Prevention of Atherothrombotic Events. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish... Leer más →
1 septiembre, 2016
Impact of statins on serial coronary calcification during atheroma progression and regression
Impact of statins on serial coronary calcification during atheroma progression and regression Puri R, Nicholls SJ, Shao M, Kataoka... Leer más →
1 septiembre, 2016
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Yusuf... Leer más →
1 septiembre, 2016
Otros fenómenos trombóticos arteriales
Prevalencia y características clínicas de la enfermedad arterial periférica en la población general del estudio Hermex
[vc_tta_accordion... Leer más →
4 agosto, 2016
Treatment of thromboangiitis obliterans (Buerger’s disease) with bosentan
[vc_row... Leer más →
4 agosto, 2016
Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study
[vc_tta_accordion... Leer más →
4 agosto, 2016
Clinical efficacy and safety of cilostazol: a critical review of the literature
Cilostazol... Leer más →
4 agosto, 2016
Cardiopatía isquémica
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
[vc_tta_accordion style="flat"... Leer más →
3 agosto, 2019
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation
Renato D. Lopes, M. et al, March 17, 2019, at NEJM.org. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in... Leer más →
3 agosto, 2019
Detection of significant coronary artery disease by noninvasive anatomical and functional imaging
[vc_row top_padding="30"... Leer más →
21 junio, 2016
Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes
Cross-trial comparisons... Leer más →
20 junio, 2016
Prehospital ticagrelor in ST-segment elevation myocardial infarction
Montalescot G, van 't Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. N Engl J Med.... Leer más →
15 junio, 2016
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, et al. N Engl J Med. 2013;368(15):1379-1387... Leer más →
15 junio, 2016
Enfermedad cerebrovascular
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
Powers WJ, Rabinstein AA, et al. American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With... Leer más →
3 agosto, 2019
A randomized trial of intraarterial treatment for acute ischemic stroke
A randomized trial of intraarterial treatment for acute ischemic stroke Berkhemer OA, Fransen PS, Beumer D, van den Berg LA,... Leer más →
16 junio, 2016
Guidelines for the treatment of acuteischaemic stroke.
Guidelines for the treatment of acuteischaemic stroke. Alonso de Leciñana M, Egido JA, Casado I, Ribó M, Dávalos A, Masjuan... Leer más →
16 junio, 2016
Embolic strokes of undetermined source: the case for a new clinical construct
[vc_column... Leer más →
16 junio, 2016
Stroke and transient ischemic attack incidence rate in Spain: the IBERICTUS study
[vc_tta_accordion style="flat"... Leer más →
16 junio, 2016
Actualización del Plan de Atención Sanitaria al Ictus II.10
[vc_tta_accordion... Leer más →
16 junio, 2016
Estratificación del riesgo embolígeno
Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study
[vc_tta_accordion style="flat"... Leer más →
20 julio, 2016
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey
A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart... Leer más →
20 julio, 2016
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with AF: nationwide cohort study
[vc_tta_accordion... Leer más →
20 julio, 2016
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach. The Euro Heart Survey on Atrial Fibrillation
[vc_tta_section i_icon_fontawesome="fa fa-folder-open-o"... Leer más →
20 julio, 2016
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation
[vc_tta_section... Leer más →
20 julio, 2016
Antiagregantes clásicos
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes
[vc_row... Leer más →
21 junio, 2016
Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2
[vc_tta_section i_icon_fontawesome="fa fa-folder-open-o" title="Abstract"... Leer más →
16 junio, 2016
Randomized comparative trial of triflusal and aspirin following acute myocardial infarction
[vc_row... Leer más →
16 junio, 2016
Anticoagulantes clásicos
Use of direct oral anticoagulants in antiphospholipid syndrome
The direct oral... Leer más →
27 mayo, 2019
“Atrial Fibrillation and Malignancy: The Clinical Performance of Non–Vitamin K Oral Anticoagulants—A Systematic Review”
[vc_tta_section i_icon_fontawesome="fa... Leer más →
27 mayo, 2019
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data Heneghan C, Ward A, Perera R, Bankhead C,... Leer más →
16 junio, 2016
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium
[vc_tta_accordion... Leer más →
16 junio, 2016
Treatment and prevention of heparin-induced thrombocytopenia. Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
Dr. Juan Carlos Souto Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Chest.... Leer más →
16 junio, 2016
Nuevos anticoagulantes
Idarucizumab for Dabigatrán Reversal – Full Cohort Analysis
Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM,... Leer más →
3 agosto, 2019
Dual Antithrombotic Therapy with Dabigatrán after PCI in Atrial Fibrillation
Cannon CP1, Bhatt DL1, Oldgren J1, Lip GYH1, Ellis SG1, Kimura T1, Maeng M1, Merkely B1, Zeymer U1, Gropper S1,... Leer más →
3 agosto, 2019
Uninterrupted Dabigatrán versus Warfarin for Ablation in Atrial Fibrillation
Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K,... Leer más →
3 agosto, 2019
Comparison of Dabigatrán and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, Clemens A, Reilly PA, Connolly SJ, Yusuf S,... Leer más →
3 agosto, 2019
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
[vc_row... Leer más →
17 junio, 2016
Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation
Novel oral anticoagulants, including dabigatran,... Leer más →
17 junio, 2016
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study
[vc_tta_accordion... Leer más →
17 junio, 2016
Dabigatran versus warfarin in patients with atrial fibrillation
[vc_row... Leer más →
17 junio, 2016
Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians. Evidence-based clinical practice guidelines.
Parenteral anticoagulants. Antithrombotic therapy and prevention of thrombosis. 9th ed: American College of Chest Physicians. Evidence-based clinical practice guidelines. Garcia... Leer más →
16 junio, 2016
Edoxabán
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism Gary E. Raskob, Ph.D., Nick van Es, M.D., Peter Verhamme, M.D., Marc Carrier, M.D., Marcello Di... Leer más →
27 mayo, 2019
Efficacy and Safety of Edoxaban in Patients With Active Malignancyand Atrial Fibrillation: Analysis of the ENGAGE AF-TIMI 48 Trial
[vc_row top_padding="30"... Leer más →
27 mayo, 2019
Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants
The acute phase of venous thromboembolism... Leer más →
17 junio, 2016
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, et al. N Engl J Med. 2013;369(15):1406-1415... Leer más →
17 junio, 2016
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. N Engl J Med. 2013;369(22):2093-2104... Leer más →
17 junio, 2016
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Edoxaban is a once-daily oral anticoagulant... Leer más →
17 junio, 2016
Efficacy and safety of edoxaban in comparison with dabigatran, Rivaroxaban and apixaban for stroke prevention in atrial fibrillation An indirect comparison analysis
[vc_tta_section i_icon_fontawesome="fa... Leer más →
12 junio, 2016
Importancia de las complicaciones derivadas del tratamiento antitrombótico
Increased risk of thrombosis in antiphospholipid síndrome patients treated with direct oral anticoagulants. Results from international patient-level data metaanálisis Autoinmunity Reviews
“Increased risk of thrombosis in antiphospholipid síndrome patients treated with direct oral anticoagulants. Results from international patient-level data metaanálisis Autoinmunity... Leer más →
27 mayo, 2019
Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents
Target-specific oral anticoagulants (TSOACs) dabigatran, rivaroxaban... Leer más →
20 junio, 2016
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation
[vc_tta_accordion... Leer más →
20 junio, 2016
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials
[vc_tta_section i_icon_fontawesome="fa fa-folder-open-o" title="Abstract"... Leer más →
20 junio, 2016
Riesgos y manejo de los sangrados con ACO (warfarina/NACOS)
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. FULL STUDY REPORT OF ANDEXANET ALFA FOR BLEEDING ASSOCIATED WITH FACTOR... Leer más →
3 agosto, 2019
Idarucizumab for Dabigatran Reversal
Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Berstein RA, et al. IDARUCIZUMAB FOR DABIGATRAN REVERSAL.N Engl J... Leer más →
20 junio, 2016
Antidotes for novel oral anticoagulants: current status and future potential
The... Leer más →
20 junio, 2016
